Physician profile
Steven B Masters
NPI 1255375671
$5,422.01
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $1,071 · 2021: $1,527 · 2022: $1,186 · 2023: $17.24 · 2024: $16.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $926.84 | 2019-2022 | |
| Amgen INC. | $559.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.99 | 2019-2022 | |
| Abbvie INC. | $452.04 | 2021-2022 | |
| Novo Nordisk INC | $387.22 | 2019-2022 | |
| Pfizer INC. | $288.32 | 2019-2022 | |
| Amarin Pharma, INC. | $190.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $188.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $182.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $162.07 | 2019-2022 | |
| Allergan, INC. | $160.51 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $138.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $125.77 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.99 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $119.89 | 2019-2022 | |
| Genentech USA, INC. | $76.92 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.84 | 2021-2023 | Camzyos |
| Astellas Pharma US INC | $56.31 | 2019-2022 | |
| Daiichi Sankyo INC. | $50.48 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $40.29 | 2021 | |
| Horizon Therapeutics Plc | $39.10 | 2021-2022 | |
| Abbott Laboratories | $38.94 | 2019-2024 | Eterna |
| Lilly USA, LLC | $37.17 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $29.75 | 2020 | |
| Medtronic Vascular, INC. | $27.05 | 2020 | |
| Mannkind Corporation | $27.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.33 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $22.93 | 2020 | |
| Zyla Life Sciences, INC. | $22.19 | 2019 | |
| Esperion Therapeutics, INC. | $19.38 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.52 | 2020 | |
| Alkermes, INC. | $17.52 | 2022 | |
| Inogen, INC. | $17.20 | 2022 | |
| Dexcom, INC. | $16.68 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.69 | 2019 | |
| Shire North American Group INC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.